“One of the distributors who has brought in has indicated that they expect to buy out in the third quarter. And the quantum of that buyout has been indicated to be $150 million.”

In context

“me items in the quarter for GARDASIL. We had exceptional growth, that growth was driven by every geography around the world. As we think about the second half of the year though, we do expect shipments to China to be less than they were in the first half of the year and therefore expect the second half of the year growth to be slower than what we've achieved in the first half. For KEYTRUDA, we had a very strong quarter, and that strength was across all indications, including the earlier-stage cancer indications that we’re launching. In the United States, we had sales of $3.9 billion, a growth of 21%. Now that growth included approximately $50 million of benefit because wholesaler buy-in in the second quarter of 2023 was slightly higher than the buy-in we saw in the second quarter of 2022. One of the distributors who has brought in has indicated that they expect to buy out in the third quarter. And the quantum of that buyout has been indicated to be $150 million. That said, we continue to expect strong growth from KEYTRUDA given the current indications we have as well as new launches to come. Peter Dannenbaum: Thanks, Mohit. Next question please, Cedric. Operator: Yes. Our next question comes from Louise Chen with Cantor. Your line is open. Louise Chen: Hi. Thank you for taking my questions. I just wanted to ask you on your Prometheus Phase III clinical trial, if you could give more color on the trial designs and then when you'll start those. And then if you'll pursue any other indications outside of IBD. Thank you. Dean Li: Yeah, so I'll take that. Thank you very much for the question in relationship to the Prometheus. Again, I just want to level set, for inflammatory bowel disease, there's a lot of cycling of anti-cytokines and then other mechan”